Since piloting the development of a plain language summary (PLS) of a congress abstract back in 2018, Pfizer have now established a company-wide program for developing PLS. So far in 2021, they have developed 116 PLS for 46 products across the company, demonstrating their commitment to this important initiative ensuring their publications are accessible and understandable by all.
With extensive experience in this area, in the latest article in the MAP Newsletter, the official newsletter of the International Society for Medical Publication Professionals, Pfizer desribe their experience integrating PLS into their standard practices for publications.
Sharing a wealth of insights into why, when and how PLS should be developed, this article is an essential read for everyone in the publications field wanting to learn how to implement their own PLS program.
Read the article in full here.